SOYACAL 10% (soybean oil) by HBM Alpha Therapeutics is patients, providing macronutrients (amino acids, dextrose and lipids) and micronutrients (electrolytes) parenterally. First approved in 1983.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
SOYACAL 10% is a parenteral nutrition injectable containing soybean oil that delivers macronutrients (amino acids, dextrose, lipids) and micronutrients (electrolytes) to patients unable to eat or absorb nutrients orally. It provides essential fatty acids and calories through lipid metabolism via beta-oxidation, supporting protein synthesis, energy production, and membrane function. This is a legacy nutritional support therapy used in hospital and clinical nutrition settings.
Product approaching loss of exclusivity with moderate competitive pressure (30% intensity) and no open clinical pipeline, suggesting a consolidating or defensive commercial structure.
patients, providing macronutrients (amino acids, dextrose and lipids) and micronutrients (electrolytes) parenterally. The amino acids provide the structural units that make up proteins and are used to synthesize proteins and other biomolecules or are oxidized to urea and carbon dioxide as a source…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Soybean Oil Trial of cArdiovascular Risk
Study Comparing a Soybean Oil-Based With an Olive Oil-Based Lipid Emulsion in ICU Patients Requiring TPN
Comparing Soybean Oil-Based (Intralipid) With an Olive Oil-Based (ClinOleic) Lipid Emulsion on Healthy Volunteers
Worked on SOYACAL 10% at HBM Alpha Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on SOYACAL 10% offers limited career upside in innovation but strong opportunities in operational excellence, regulatory stewardship, and mature-market management. This is a solid role for professionals seeking stability and expertise in parenteral nutrition markets, but not a launchpad for rapid advancement or product expansion.